Centre for Urological Research

Around 50 percent of Australian men experience some type of prostate problem during their lifetime. Prostate cancer is one of the most common forms of cancer in men. Approximately 10,000 cases are diagnosed and 2500 deaths occur each year. Benign prostate disease (BPH) is equally significant – 90 percent of all men aged over 80 will have this condition. Whilst not life threatening, BPH can have a dramatic effect on quality of life, and its management remains a pressing problem.

The Centre for Urological Research (CURe) in partnership with its Clinical Director, Associate Professor Mark Frydenberg, aims to provide better diagnosis and treatments for prostate cancer and benign prostate disease (BPH). Working in modern laboratories, scientists and clinicians are working together and with industry to develop more specific tests to distinguish between cancer and benign disease, and between fast and slow growing tumours.

Understanding how prostate stem cells are regulated in normal as well as diseased tissue, underpins the development of novel diagnostic and therapeutic strategies.

To compliment CURe's prostate cancer research, MIMR has become the Victorian branch of the Australian Prostate Cancer BioResource, a national prostate tissue bank.


CURe's scientists and doctors work closely with universities, hospitals and other research institutes in Australia and overseas. Their wide range of commercial activities enable their research to continue to advance.